The proliferation of the B14.3 HER2 tumor cells was not directly affected by treatment with Trastuzumab (Fig 6A), highlighting that any change of tumor growth that would be observed in vivo would come from an indirect effect. This evidence concerns the gene ERBB2 and neoplasm.